Company Profile

Main Business Activities:

R&D of medicines and external diagnostic drugs based on monoclonal antibodies

1)We made the brand new monoclonal antibody (mAb) against a new colorectal cancer (CRC) specific molecule obtained after comprehensive expression analysis between the pure mucoepithelial cells and CRC cell line.
The antigen is circulating in blood stream in patients with CRC and therefore we are developing a new blood test for CRC. Furthermore, we are developing the new antibody therapeutics using the mAb because the mAb appears to possess a robust ADCC function and in vivo antitumor activity.

2)We successfully developed an mAb that reacted only with human fibrin, not with human fibrinogen and cross-reacted with mouse fibrin but not with mouse fibrinogen. The specificity of our mAb differs from existing anti-fibrin mAbs. Namely, the mAb reacts only with fibrin clot, but not with fibrinogen, soluble fibrin, or D-dimer. The anti-fibrin antibody therefore did not make immune complex in the blood stream and circulated in the blood for a long time. We then prepared the antibody drug conjugate (ADC) that is MMAE conjugated anti-fibrin mAb. The ADC may selectively extravasate from leaky tumor vessels, bind to the fibrin network in the stroma and create a scaffold from which effective sustained release of the free MMAE occur. This free MMAE may easily reach the cancer cells by diffusion through the stroma barrier. Another benefit is that MMAE released from the ADC may also attack the vascular endothelial cells.

What's RIN?

The company name "RIN " is the abbreviation for Robust Immuno-diagnosis and therapy against malignant Neoplasm.
Another origin of the company name: RIN derives from the name of one of the founders' granddaughter "Rinko".

R&D of RIN Institute Inc. is headed by: Yasuhiro Matsumura, MD, PhD

  • 1981 MD from Kumamoto University Trainee, 1st Department of Surgery, Kumamoto University
  • 1988 PhD from Kumamoto University
  • 1989 Postdoctoral fellow of Department of Neoplastic Diseases, Mt Sinai Medical Center, NY, USA
  • 1990-1994 Postdoctoral fellow of Nuffield Department of Pathology Oxford University UK
  • 1994-1999 Staff Physician, Department of Medicine, National Cancer Center Hospital.
  • 1999-2002 Head of Department of Medicine, National Cancer Center Hospital
  • 2002- Director of Division of Developmental Therapeutics, EPOC, National Cancer Center
Research achievements
1) Cancer induced intrinsic blood coagulation: Discovery of unexplored holes on fibrin clot and development of its monoclonal antibody (mAb). Proposal of CAST therapy. Discovery of EPR effect and Hyp3-bradykinin
2) Development of mAbs: Identification of colorectal cancer marker and the development of the mAb. Identification of CD44 variant 2 and the development of the mAb
Company Name RIN Institute Inc.
Date founded January 21,2016
Company Address Shintomi Bldg. 3F, 2-5-10, Shintomi, Chuo-ku, Tokyo, 104-0041, Japan
President Kentaro Yoshimatsu